Eton Pharmaceuticals Inc. Stock News

DEER PARK, Ill., Oct. 18, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals (“Eton” or “the Company”) (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing

Eton Pharmaceuticals, Inc. (NASDAQ:ETON ) Q2 2022 Earnings Conference Call August 11, 2022 4:30 PM ET Company Participants David Krempa - Senior Vice President of Business Development & Investor Relat

Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of -300% and 5.30%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock

Eton Pharmaceuticals (ETON) stock is on the rise Monday as investors react to news of approval from the FDA for Zonisade. The post Eton Pharmaceuticals (ETON) Stock Is Up 10% on FDA Approval appeared

Eton Pharmaceuticals Inc (NASDAQ: ETON) shares are trading higher Monday after the company announced FDA approval of ZONISADE. ZONISADE was included in Eton's multi-product partnership with Azurit

Shares of Eton Pharmaceuticals Inc. ETON, +3.33% jumped 16.5% in premarket trading on Monday after the company said the Food and Drug Administration approved Zonisade, a seizure treatment for adults a

Eton Pharmaceuticals Inc (NASDAQ: ETON) has sold its hospital products to Dr. Reddy's Laboratories SA, a subsidiary of Dr. Reddy's Laboratories Ltd (NYSE: RDY), for $50 million. "The sale of our

Eton Pharmaceuticals, Inc. (ETON) delivered earnings and revenue surprises of -162.50% and 69.21%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the

Eton Pharmaceuticals, Inc. (NASDAQ:ETON ) Q1 2022 Earnings Conference Call May 12, 2022 4:30 PM ET Company Participants David Krempa – Senior Vice President-Business Development and Investor Relatio

Eton Pharmaceuticals, Inc. (ETON) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Eton Pharmaceuticals, Inc. (ETON) CEO Sean Brynjelsen on Q4 2021 Results - Earnings Call Transcript

DEER PARK, Ill., March 08, 2022 (GLOBE NEWSWIRE) -- Eton Pharmaceuticals, Inc (Nasdaq: ETON), an innovative pharmaceutical company focused on developing and commercializing treatments for rare diseases, today announced that it will report fourth quarter 2021 financial results on Wednesday, March 16, 2022. Due to the company’s cysteine product Paragraph IV litigation trial taking place during business hours on March 16, management will host a conference call and live audio webcast to discuss these results at 7:00 p.m. ET (6:00 p.m. CT).

Zacks Investment Research downgraded shares of Harrow Health (NASDAQ:HROW) from a buy rating to a hold rating in a research note released on Thursday morning, Zacks.com reports. According to Zacks, Harrow Health Inc. owns a portfolio of healthcare businesses, including an ophthalmology pharmaceutical compounding business, ImprimisRx. The company holds Eton Pharmaceuticals, Surface Pharmaceuticals, Melt Pharmaceuticals, [] The post Harrow Health (NASDAQ:HROW) Downgraded by Zacks Investment Research appeared first on ETF Daily News .

SNAX, ETON, AVYA, DLB, and ROCC have been added to the Zacks Rank #5 (Strong Sell) List on December 14, 2021